Cigna Pathwell Specialty^® is for patients using specialty medication to treat complex medical conditions. As part of this program, certain medications must be administered by a provider that participates in the Cigna Pathwell Specialty program or ordered from an in-network specialty pharmacy to be covered.

As part of our ongoing review, we periodically update the Pathwell Specialty drug list.

What’s changing

Effective September 10, 2026, the following drugs were added to the Pathwell Specialty drug list:

• CLIGAVYX^TM fulvestrant
• LUMVOA^TM veligrotug-vvze

Effective September 10, 2026, the following drugs were added to the Pathwell Specialty drug list:

• Omlyclo® omalizumab-igec
• Revtorpyk^TM gedatolisib
• Sarclissa Escena^TM isatuximab-irfc

Effective October 1, 2026, the following drugs were added to the Pathwell Specialty drug list:

• Armlupeg^TM pegfilgrastim-unne
• Pasatru^TM garetosmab-grts
• ZANVASTRO^TM zilganersen
• TUDRIQEV vusolimogene oderparepvec-wtpg

Effective January 1, 2027, the following drugs were added to the Pathwell Specialty drug list:

• Jelmyto® mitomycin
• Rylaze® asparaginase erwinia chrysanthemi (recombinant)-rywn
• Zynyz® retifanlimab-dlwr

What this means for providers For the medications listed above, a Pathwell Specialty designated provider is no longer required for administration or acquisition. Standard prior authorization process for medical necessity will continue to apply according to the patient’s plan benefits. Medical necessity requirements are outlined in the coverage policies available at CignaforHCP.com > Get questions answered: Resource > Coverage Policies.

Additional information

Medications not included on the Pathwell Specialty drug list are not required to be administered by a Pathwell Specialty designated provider.

For the most up‑to‑date information, including participating providers, visit the Cigna Pathwell Specialty website.